Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
S&P report gives company 'bullish' rating for Alzheimer urine test, others
June 6th, 2005
Nymox Pharmaceutical Corporation (NYMX) received favorable coverage in a new Standard & Poor's (S&P) Stock Report, which rates Nymox stock as "bullish" on technical evaluation. The stock report, written by S&P analyst Craig C. Pratesi, analyzes the company's business activities and stock performance. Th report follows recent positive news from the company in its recent announcement that AlzheimAlert urine test was advancing to a meeting of an U.S. Food and Drug Administration (FDA) advisory panel. The company also announced that it had signed marketing and distribution deals for this product in Italy with Alifax S.p.A. and in the...
Source: Biotech Business Week (2005-06-06)
|
